JNJ-64400141
- Generic Name
- JNJ-64400141
A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older
Phase 1
Terminated
- Conditions
- Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 132
- Registration Number
- NCT05327816
- Locations
- ๐บ๐ธ
Floridian Clinical Research LLC, Miami Lakes, Florida, United States
๐บ๐ธArk Clinical Research, Long Beach, California, United States
๐บ๐ธAccel Research Sites, DeLand, Florida, United States
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age
Phase 1
Completed
- Conditions
- Respiratory Syncytial Virus
- Interventions
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 38
- Registration Number
- NCT03606512
- Locations
- ๐ง๐ท
Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil
๐ง๐ทUniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS, Porto Alegre, Brazil
๐ซ๐ฎTurun rokotetutkimusklinikka, Turku, Finland
A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health
Phase 2
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 180
- Registration Number
- NCT03339713
- Locations
- ๐บ๐ธ
Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States
An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 64
- Registration Number
- NCT03334695
- Locations
- ๐ฌ๐ง
hVIVO Services Limited, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2025. All Rights Reserved by MedPath